老年惰性B细胞淋巴瘤一线BR与RCHOP/RCVP的真实世界结局比较
该研究基于2009-2016年Medicare受益人数据,倾向性评分匹配后比较老年滤泡性、套细胞或边缘区/淋巴浆细胞淋巴瘤患者一线苯达莫司汀/利妥昔单抗(BR)与环磷酰胺为基础方案(RCHOP/RCVP)的结局。汇总队列(N=2736)中BR组无事件生存(EFS)更优(HR 0.78),急性毒性更低,但总生存(OS)无差异(HR 1.03),且Medicare支出更高;EFS优势在套细胞淋巴瘤最明显,在边缘区/淋巴浆细胞淋巴瘤中不存在。
要点
- 汇总队列中BR较RCHOP/RCVP改善EFS(HR 0.78),但OS无差异(HR 1.03)。
- BR组急性毒性更低,包括住院率(33% vs 45%)和感染率(21% vs 30%)。
- BR的EFS优势在套细胞淋巴瘤最显著(HR 0.64),边缘区/淋巴浆细胞淋巴瘤中无优势。
核心结论
- 尽管BR较RCHOP/RCVP改善EFS并降低毒性,但临床实践中从RCHOP/RCVP转向BR并未改善老年惰性B细胞淋巴瘤患者的OS。
研究设计与样本
- 回顾性队列研究,纳入2009-2016年接受一线BR或RCHOP/RCVP的Medicare受益人,按倾向性评分匹配。
- 汇总队列N=2736,并分别匹配组织学亚型亚组:滤泡性淋巴瘤N=1330、套细胞淋巴瘤N=690、边缘区/淋巴浆细胞淋巴瘤N=574。
主要发现
- 汇总队列中BR组EFS优于RCHOP/RCVP组(HR 0.78;95%CI 0.70-0.87)。
- BR组急性毒性更低,住院率33% vs 45%、感染率21% vs 30%,心血管事件和输血也更少。
- 两组OS无差异(HR 1.03;95%CI 0.91-1.17),第二肿瘤累积发生率无差异(亚风险比1.11;95%CI 0.83-1.48)。
- BR的EFS优势在套细胞淋巴瘤显著(HR 0.64;95%CI 0.54-0.76),滤泡性淋巴瘤较弱(HR 0.83;95%CI 0.69-0.98),边缘区/淋巴浆细胞淋巴瘤无优势(HR 0.92;95%CI 0.73-1.17)。
临床怎么用
- 老年惰性B细胞淋巴瘤选择一线方案时,BR可改善EFS并降低急性毒性,但未显示OS获益。
- 套细胞淋巴瘤患者可能从BR获得更明显的EFS优势,边缘区/淋巴浆细胞淋巴瘤则未见优势。
- BR组感染和住院仍常见,需关注安全性并探索更安全的治疗策略。
局限性
- 研究基于Medicare理赔数据,EFS为理赔定义的事件无进展生存,可能存在编码偏倚。
- 为回顾性观察性设计,倾向性评分匹配不能完全排除混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials comparing bendamustine/rituximab (BR) with cyclophosphamide-based regimens (RCHOP/RCVP) have pooled various histologies of indolent B-cell lymphomas. We examined real-life outcomes of older patients with follicular (FL), mantle cell (MCL), or marginal zone/lymphoplasmacytic lymphoma (MZL/LPL), treated with these first-line regimens. We identified Medicare beneficiaries with FL, MCL, or MZL/LPL, who received either first-line BR or RCHOP/RCVP in 2009-2016, and matched groups using a propensity score. Outcomes of claims-based event-free survival (EFS), overall survival (OS), toxicity, secondary cancers, and costs were compared in the aggregate cohort (N = 2736), and in separately matched histology-specific subcohorts. In the aggregate cohort, EFS was better with BR than with RCHOP/RCVP (hazard ratio [HR], 0.78; 95% confidence interval [CI], 0.70-0.87). Acute toxicity was lower with BR, including rates of hospitalizations (33% vs 45%), infections (21% vs 30%), cardiovascular events, and transfusions, yet OS did not differ (HR, 1.03; 95% CI, 0.91-1.17) and Medicare spending was higher. There was no difference in the cumulative incidence of secondary cancers (subhazard ratio, 1.11; 95% CI, 0.83-1.48). The EFS advantage of BR was pronounced in MCL (N = 690; HR, 0.64; 95% CI, 0.54-0.76), but less so in FL (N = 1330; HR, 0.83; 95% CI, 0.69-0.98) and absent in MZL/LPL (N = 574; HR, 0.92; 95% CI, 0.73-1.17). Despite improved EFS and lower toxicity, the shift from RCHOP/RCVP to BR in clinical practice did not improve OS for older patients with indolent B-cell lymphomas. Frequent infections and hospitalizations underscore the need for safer treatment approaches in this population. Secondary cancers do not appear to be increased after BR compared with RCHOP/RCVP.
引用
- Olszewski AJ, Butera JN, Reagan JL, et al. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2020. PMID: 31849108. doi:10.1002/ajh.25707
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。